Jafron Biomedical (300529.SZ) plans to acquire a 37.6% stake in Aiduoduo to improve its full industry chain layout for blood purification.
Jianfan Biological (300529.SZ) announced that the company intends to acquire 37.60% equity of Aiduoduo Health Management (Guangdong Hengqin) Co., Ltd. (Aiduoduo) with its own funds, for a transfer price of 17.592 million yuan. Prior to this transaction, Aiduoduo was a holding subsidiary of the company, with a 62.40% stake, mainly engaged in health management and guarantee services in the field of chronic diseases, focusing on providing personalized health management plans and health consultation services, such as popular science education, for patients with chronic kidney disease. After the transaction, the company will hold 100% equity of Aiduoduo, making Aiduoduo a wholly-owned subsidiary of the company, which is conducive to promoting the synergistic development of the business between the company and Aiduoduo, and will help further improve the company's full industry chain layout in blood purification.
Jafron Biomedical (300529.SZ) announced that the company intends to use its own funds to acquire 37.60% equity in Aiduoduo Health Management (Guangdong Hengqin) Co., Ltd. (referred to as Aiduoduo), with the corresponding purchase price of 17.592 million yuan. Prior to this transaction, Aiduoduo was a subsidiary of the company holding 62.40% of the shares and primarily engaged in health management and protection services in the chronic disease sector, focusing on providing personalized health management plans and health consultation services such as popular science education for chronic kidney disease patients. After the transaction, the company will hold 100% equity in Aiduoduo, making Aiduoduo a wholly-owned subsidiary of the company. This move is conducive to promoting the synergistic development of both the company and Aiduoduo's business and helps further improve the company's full industrial chain layout in blood purification.
Related Articles
EB SECURITIES: Maintains a "Buy" rating on COWELL (01415), optimistic about its continued growth amid the trend of optical upgrades in smartphones.
EB SECURITIES: Maintains Buy Rating for CONANT OPTICAL (02276) as XR Business Achieves Breakthrough Progress
Keysight Technologies Inc (KEYS.US) Q3 earnings report and guidance both exceeded expectations: Demand from AI data centers drove a year-on-year order surge of 56%, and commercial communications revenue broke $1 billion for the first time.
EB SECURITIES: Maintains a "Buy" rating on COWELL (01415), optimistic about its continued growth amid the trend of optical upgrades in smartphones.
EB SECURITIES: Maintains Buy Rating for CONANT OPTICAL (02276) as XR Business Achieves Breakthrough Progress
Keysight Technologies Inc (KEYS.US) Q3 earnings report and guidance both exceeded expectations: Demand from AI data centers drove a year-on-year order surge of 56%, and commercial communications revenue broke $1 billion for the first time.
RECOMMEND
